Stiris Research Inc. Announces Enrollment of First Patient in Paraoxysmal Nocturnal Hemoglobinuria Study.

London, ON — March 4, 2022 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the enrollment of the first patient in a Paraoxysmal nocturnal hemoglobinuria (PNH) study.

“We just enrolled our first patient in the US and are excited to start this study in North America. We will be initiating our first site in Canada this month as well,” said Lisa Hall, Project Manager. “Our highly experienced team is looking forward to working in getting these new treatments into patients suffering from rare diseases,” said Amanda Carrera, Vice President.

Paraoxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood. The disease is characterized by destruction of red blood cells, blood clots, and impaired bone marrow function. PNH is closely related to aplastic anemia.


About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS/Neurology, Endocrinology and Rare Disease. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.